Skip to search formSkip to main contentSkip to account menu

LU 103793

Known as: LU-103793, LU103793 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

cemadotincemadotin hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Activity of the dolastatin analogue, LU103793, in malignant melanoma.
LU103793, a synthetic analogue of dolastatin 15, showed interesting pre-clinical activity in melanoma xenografts. In this phase… 
1998
1998
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic profile of the… 
1996
1996
Phase I Clinical and Pharmacokinetic Study of LU103793 (Cemadotin Hydrochloride) as an Intravenous Bolus Injection in Patients with Metastatic Solid Tumors
Background: To study the toxicity and pharmacokinetics of LU103793 (Cematodin®), a novel cytotoxic anticancer drug being an… 
Highly Cited
1995
Highly Cited
1995
LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis.
LU103793 (NSC D-669356) is a new synthetic derivative of Dolastatin 15, an antiproliferative compound which was isolated from the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)